Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $353.88 million. The enterprise value is $102.33 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 56.62 million shares outstanding. The number of shares has increased by 0.91% in one year.
| Current Share Class | 56.62M |
| Shares Outstanding | 56.62M |
| Shares Change (YoY) | +0.91% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 15.61% |
| Owned by Institutions (%) | 37.76% |
| Float | 25.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.40 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.61, with a Debt / Equity ratio of 0.01.
| Current Ratio | 34.61 |
| Quick Ratio | 34.35 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -17.78% and return on invested capital (ROIC) is -13.99%.
| Return on Equity (ROE) | -17.78% |
| Return on Assets (ROA) | -13.54% |
| Return on Capital (ROIC) | -13.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$823,776 |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +136.74% in the last 52 weeks. The beta is 1.86, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | +136.74% |
| 50-Day Moving Average | 5.88 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 52.38 |
| Average Volume (20 Days) | 208,423 |
Short Selling Information
The latest short interest is 2.71 million, so 4.79% of the outstanding shares have been sold short.
| Short Interest | 2.71M |
| Short Previous Month | 2.69M |
| Short % of Shares Out | 4.79% |
| Short % of Float | 10.74% |
| Short Ratio (days to cover) | 19.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | -43.21M |
| Operating Income | -60.81M |
| Pretax Income | -50.53M |
| Net Income | -47.78M |
| EBITDA | -60.23M |
| EBIT | -60.81M |
| Earnings Per Share (EPS) | -$0.85 |
Full Income StatementBalance Sheet
The company has $254.07 million in cash and $2.52 million in debt, giving a net cash position of $251.55 million or $4.44 per share.
| Cash & Cash Equivalents | 254.07M |
| Total Debt | 2.52M |
| Net Cash | 251.55M |
| Net Cash Per Share | $4.44 |
| Equity (Book Value) | 252.45M |
| Book Value Per Share | 4.46 |
| Working Capital | 249.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$46.04 million and capital expenditures -$367,000, giving a free cash flow of -$46.41 million.
| Operating Cash Flow | -46.04M |
| Capital Expenditures | -367,000 |
| Free Cash Flow | -46.41M |
| FCF Per Share | -$0.82 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |